某三甲医院双通道药品处方回顾性分析

Retrospective Analysis of“Double Channel”Prescriptions in Outpatients of a ClassⅢGrade A Hospital

目的通过对泉州某三甲医院某院区双通道药品处方进行整合和分析,评价我院双通道药品的使用情况。方法通过CHIS中国医院信息系统采集2021年1月至2023年10月门诊双通道药品使用情况。结果双通道药品在我院的处方量逐年增加。其中风湿免疫系统药物处方量占比最高(30.2%),其次是抗肿瘤药(26.1%)、皮肤用药(15.9%)和内分泌系统药物(11.2%)。从处方金额来看,抗肿瘤药的处方金额最高,占处方总金额的43.7%。其次是风湿免疫系统药物、皮肤用药、呼吸系统药物和内分泌系统药物。结论双通道政策满足了谈判药品的供应保障和临床使用等需求,提高了谈判药品的可及性。

OBJECTIVE To integrate and analyze the prescriptions of Double Channel in outpatient pharmacy of a ClassⅢGrade A hospital in Quanzhou City,and to evaluate the rationality of drug use by clinicians in our hospital.METHODS The use of“Double Channel”drugs in outpatient clinics from 2021 to October 2023 was collected through CHIS Chinese Hospital Information System.RESULTS The prescription quantity of double-channel drugs in our hospital is increasing year by year.Among them,rheumatism and immune system drugs accounted for the highest proportion(30.2%),followed by antineoplastic drugs(26.1%),skin drugs(15.9%)and endocrine system drugs(11.2%).In terms of prescription amount,the prescription amount of antineoplastic drugs was the highest,accounting for 43.7%of the total prescription amount,followed by rheumatoid immune system drugs,skin drugs,respiratory system drugs and endocrine system drugs.CONCLUSION The double-channel policy meets the needs of supply security and clinical use of negotiated drugs,and improves the accessibility of negotiated drugs.